Bringing out European nuggets in health technologies is the objective of the fund launched by Pierre Moustial, the former boss of Urgo.
His company, Lauxera Capital Partners, raised 100 million euros in less than six months from investors such as Tethys, the holding company of the Bettencourt family, Financière Dassault, the insurer Covéa, Bpifrance and the company of European asset management Candriam, a subsidiary of the American insurer New York Life.
“
Our goal is to become the European
leader
in the medical device and e-health
segment
,”
explains Pierre Moustial.
We are the first investor entirely dedicated to healthtech
. ”
Read also:
The Covid-19, accelerator of digital transformation in health
This pure player in health technologies will strengthen the European ecosystem which is taking shape.
The French Sofinnova or Truffle Capital (Carmat, Abivax, etc.) are already playing an important role in this, alongside other European funds dedicated to health such as G Square, LSP or Earlybird.
Launched a year ago, the French fund
This article is for subscribers only.
You still have 76% to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/JFV33VNFE4U24DXYYW2DGO3HOY.jpg)
